AbbVie announced an agreement was reached with the pan-Canadian Pharmaceutical Alliance regarding Maviret, a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes. Maviret is the only 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment, who make up a large portion of HCV patients in Canada, AbbVie says in a statement.
https://thefly.com/landingPageNews.php?id=2867987
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.